Registered title, quoted from ClinicalTrials.gov
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Southwest Hospital, Army Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06760858, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Staging according to the American Joint Committee on Cancer (AJCC) 8th edition is T4aNxM0, without obstruction, perforation, or bleeding risk.
Inclusion criterion 3
Patients with newly diagnosed Her-2 negative gastric adenocarcinoma, with no prior chemotherapy, radiotherapy, or other anti-cancer treatments before the start of the clinical trial.
Inclusion criterion 1
Received corticosteroids (>10mg/day prednisone or equivalent dose of steroids) or other systemic immunosuppressive therapy within 14 days prior to enrollment, excluding the following treatments: steroid hormone replacement therapy (≤10mg/day); local steroid therapy; and short-term prophylactic steroid therapy for allergies or nausea and vomiting.
Exclusion criterion 9
Age between 18 to 80 years old, Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.
Inclusion criterion 2
International normalized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 times ULN.
Inclusion criterion 6
History of HIV infection or active hepatitis B/C virus infection.
Exclusion criterion 10
Pregnant or breastfeeding women.
Exclusion criterion 21
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06760858, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients with newly diagnosed Her-2 negative gastric adenocarcinoma, with no prior chemotherapy, radiotherapy, or other anti-cancer treatments before the start of the clinical trial.
- Age between 18 to 80 years old, Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.
- Staging according to the American Joint Committee on Cancer (AJCC) 8th edition is T4aNxM0, without obstruction, perforation, or bleeding risk.
- Good bone marrow reserve function, with the following blood criteria: white blood cell count ≥3×10\^9/L, neutrophils ≥1.5×10\^9/L, platelet count ≥100×10\^9/L, hemoglobin ≥90 g/L.
- Good organ function, with the following biochemical criteria: aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN), alanine aminotransferase (ALT) ≤2.5×ULN, serum total bilirubin ≤1.5×ULN, serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min.
- International normalized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 times ULN.
- Urine protein <2+, if urine protein ≥2+ then 24-hour urine protein quantification must be ≤1g.
- Consent to provide blood and tissue samples.
- Expected survival of more than 3 months.
- Female subjects agree to strict contraception; male subjects with partners of childbearing potential agree to use effective contraception during the study period.
- Voluntarily sign the informed consent form, willing and able to comply with planned visits, study treatments, laboratory tests, and other trial procedures.
Exclusion Criteria:
- Participants who have been enrolled in any other drug clinical trial or have participated in any drug clinical trial within the last month.
- Any anti-cancer treatments (chemotherapy, radiotherapy, surgery, immunotherapy, biotherapy, chemoembolization) other than the study medication (palliative external beam radiation for non-target lesions is allowed).
- Prior use of similar chemotherapy drugs or immune checkpoint inhibitors.
- Presence of metastatic lesions in the liver, lungs, para-aortic lymph nodes, bones, brain, adrenal glands, or pelvic and abdominal cavity.
- Gastrointestinal perforation, obstruction, or uncontrollable diarrhea within 6 months prior to enrollment.
- Other untreated or concurrent tumors, except for cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors. Patients with tumors that have been cured and have no evidence of disease for more than 5 years may be included. All other tumors must have been treated at least 5 years prior to enrollment.
- Symptomatic meningiomas:
- History of active autoimmune diseases or refractory autoimmune diseases.
- Received corticosteroids (>10mg/day prednisone or equivalent dose of steroids) or other systemic immunosuppressive therapy within 14 days prior to enrollment, excluding the following treatments: steroid hormone replacement therapy (≤10mg/day); local steroid therapy; and short-term prophylactic steroid therapy for allergies or nausea and vomiting.
- History of HIV infection or active hepatitis B/C virus infection.
- Persistent > Grade 2 bacterial, fungal, viral infections.
- Active or clinically significant cardiac disease:
- Congestive heart failure > New York Heart Association (NYHA) Class II;
- Active coronary artery disease;
- Arrhythmias requiring treatment other than beta-blockers or digoxin;
- Unstable angina (angina symptoms at rest), new-onset angina within 3 months prior to enrollment, or unhealed wounds, ulcers, or fractures due to myocardial infarction within 6 months prior to enrollment.
- Patients with renal failure requiring hemodialysis or peritoneal dialysis.
- Patients requiring medication for epilepsy.
- History of organ transplantation (including corneal transplants).
- Allergy to the study medication or similar drugs, or suspected allergies.
- Pregnant or breastfeeding women.
- Major surgery, open biopsy, or significant traumatic surgery within 4 weeks prior to recruitment.
- History of vaccination within 4 weeks prior to enrollment.
- Patients deemed unsuitable for the study by the investigator.
Quoted from ClinicalTrials.gov, NCT06760858, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06760858, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.